E.g., 07/01/2022
E.g., 07/01/2022

Quidel and bioMérieux Announce a Global Strategic Alliance in Rapid Diagnostics

15 January, 2008

Quidel Corporation (NASDAQ: QDEL) and bioMérieux (Euronext: BIM) have agreed to form a long-term global alliance in the area of rapid clinical diagnostics for the point-of-care. bioMérieux will become Quidel’s primary distributor for its QuickVue® rapid diagnostic tests outside the United States and the two companies intend to co-develop new rapid tests using Quidel’s market leading rapid test development capability and bioMérieux’s expertise and extensive library of antibodies and antigens. The companies will especially leverage their mutual expertise in the area of infectious diseases.

Sysmex and bioMérieux Form a Commercial Joint Venture for the Japanese in Vitro Diagnostics Market

10 January, 2008

Sysmex Corporation (HQ: Kobe, Japan; President: Hisashi Ietsugu) and bioMérieux (Euronext: BIM) announce they have signed an agreement by which Sysmex will take a 34% equity stake in bioMérieux Japan, Ltd.

bioMérieux Transfers Certain R&D and Manufacturing Activities to France

08 January, 2008

bioMérieux (Euronext: BIM) announces the transfer to France of R&D and certain manufacturing activities currently at its Boxtel site in the Netherlands. The transfer will take place gradually until the end of 2009, when this site closes.

Pioneering Diagnostics